Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2017-12-13 Legal Proceedings Report
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Third Party Claim 2 pages 502.7KB
Legal Proceedings Report Classification · 95% confidence The document is an ASX release dated 14 December 2017 concerning a third party legal claim against Bioxyne Limited. It discusses the filing of a statement of claim in the High Court of New Zealand and the company's intention to defend the claim. The content focuses on legal proceedings and updates related to a lawsuit, without any financial data, report publication, or management discussion. It is not an annual report, earnings release, or any financial report. The document fits the category of Legal Proceedings Report, as it provides an update on significant legal matters involving the company.
2017-12-13 English
Positive Bioxyne Gut Health Clinical Trial Results 4 pages 567.8KB
Regulatory Filings Classification · 90% confidence The document is an ASX release dated 11 December 2017, presenting preliminary positive clinical trial results for Bioxyne's probiotic product. It contains detailed scientific data and statistical findings from the clinical trial, including patient-reported outcomes and safety information. The document is a standalone announcement of clinical trial results rather than a full financial report, earnings release, or regulatory filing. It does not contain financial statements or management discussion of financial results. It is not a presentation, proxy, or governance document. Given the nature of the content—clinical trial results announcement—it best fits under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories such as earnings release or annual report. The document length (7322 characters) and detailed data support that it is more than a brief announcement but not a full financial report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2017-12-10 English
Change of Directors Interest X 3 7 pages 555.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including number of shares/options held before and after changes, nature of changes (e.g., exercise of options, on-market trades), and dates of changes. The document is a formal notification of personal share transactions by company directors. It does not contain financial performance data, earnings, or management discussion, nor is it an announcement of a report publication. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length (over 11,000 characters) and detailed transaction data confirm it is the actual report, not a brief announcement or certification. Therefore, the correct classification is DIRS (Director's Dealing).
2017-12-10 English
Appendix 3B 13 pages 774.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, exercise prices, expiry dates, and compliance with ASX listing rules. It includes sections on the calculation of placement capacity under ASX rules, quotation agreements, and shareholder approvals related to the issuance of shares. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding new share issues and related capital changes. It does not contain financial statements, management discussion, or earnings data, nor is it a report or presentation. It is clearly an announcement about new share issuance and capital structure changes, fitting the definition of a Share Issue/Capital Change filing.
2017-12-10 English
Appendix 3B Amended 13 pages 729.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, issue price, purpose of the issue, and compliance with ASX listing rules. It also includes calculations related to placement capacity under ASX rules 7.1 and 7.1A, which pertain to capital raising and share issuance limits. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new share issue and application for quotation of additional securities. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (15,000 characters) and content confirm it is the announcement itself, not just a brief notice or report publication announcement.
2017-12-06 English
Bioxyne Launches NZ Dairy Formula Product in South East Asia 5 pages 1.0MB
Capital/Financing Update Classification · 90% confidence The document is an ASX release dated 7 December 2017 announcing the launch of new products by Bioxyne in the South East Asian market. It highlights product details, initial orders, and market expansion plans. There is no financial data, no mention of quarterly or annual results, no regulatory filings, no voting results, no management changes, no merger or acquisition activity, and no legal proceedings. The document is a corporate announcement about product launches and business development activities. It fits best under Capital/Financing Update (CAP) as it relates to business expansion and product launch announcements which can impact company capital and market presence. The document length is under 5,000 characters and is a direct announcement, not a report publication or certification. Therefore, the most appropriate classification is CAP with high confidence.
2017-12-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.